S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
S&P 500   0.54 (-1.29%)
DOW   0.54 (-1.29%)
QQQ   274.64 (+1.32%)
AAPL   455.61 (+3.49%)
MSFT   216.35 (+1.60%)
FB   265.28 (+6.49%)
GOOGL   1,504.95 (+1.75%)
AMZN   3,225.00 (+0.62%)
NVDA   453.42 (+0.43%)
CGC   17.52 (-8.80%)
BABA   265.68 (+0.29%)
TSLA   1,489.58 (+0.31%)
MU   48.70 (-4.60%)
GE   6.33 (-1.09%)
AMD   86.71 (+1.64%)
T   29.84 (-0.03%)
F   6.93 (-0.43%)
ACB   10.31 (-3.73%)
GILD   68.81 (-0.28%)
NFLX   509.08 (+1.39%)
DIS   130.82 (+2.52%)
BAC   25.47 (+0.32%)
BA   172.20 (-1.19%)
Log in

NASDAQ:ZGNXZogenix Stock Price, Forecast & News

$23.69
-0.76 (-3.11 %)
(As of 08/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$23.09
Now: $23.69
$24.41
50-Day Range
$23.79
MA: $27.16
$29.69
52-Week Range
$16.65
Now: $23.69
$57.22
Volume1.07 million shs
Average Volume1.08 million shs
Market Capitalization$1.31 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.63
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California.
Read More
Zogenix logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.99 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:ZGNX
CUSIP98978L10
Phone510-550-8300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.65 million
Book Value$5.54 per share

Profitability

Net Income$-419,500,000.00
Net Margins-8,374.54%

Miscellaneous

Employees90
Market Cap$1.31 billion
Next Earnings DateN/A
OptionableOptionable
$23.69
-0.76 (-3.11 %)
(As of 08/6/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zogenix (NASDAQ:ZGNX) Frequently Asked Questions

How has Zogenix's stock been impacted by COVID-19 (Coronavirus)?

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX shares have increased by 4.4% and is now trading at $23.69.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Zogenix?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zogenix
.

How were Zogenix's earnings last quarter?

Zogenix, Inc. (NASDAQ:ZGNX) announced its quarterly earnings results on Wednesday, August, 5th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.02) by $0.06. Zogenix had a negative net margin of 8,374.54% and a negative return on equity of 47.19%.
View Zogenix's earnings history
.

What price target have analysts set for ZGNX?

11 equities research analysts have issued 12 month price objectives for Zogenix's stock. Their forecasts range from $27.00 to $78.00. On average, they expect Zogenix's share price to reach $56.80 in the next twelve months. This suggests a possible upside of 139.8% from the stock's current price.
View analysts' price targets for Zogenix
.

Has Zogenix been receiving favorable news coverage?

News headlines about ZGNX stock have trended negative recently, according to InfoTrie. The research group scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zogenix earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days.
View the latest news about Zogenix
.

Who are some of Zogenix's key competitors?

What other stocks do shareholders of Zogenix own?

Who are Zogenix's key executives?

Zogenix's management team includes the following people:
  • Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)
  • Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)
  • Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)
  • Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)
  • Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer

What is Zogenix's stock symbol?

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Who are Zogenix's major shareholders?

Zogenix's stock is owned by many different retail and institutional investors. Top institutional investors include Candriam Luxembourg S.C.A. (1.71%), Emerald Advisers LLC (1.13%), Emerald Mutual Fund Advisers Trust (1.03%), International Biotechnology Trust PLC (0.43%), GW&K Investment Management LLC (0.33%) and Swiss National Bank (0.21%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Erle T Mast, Gail M Farfel, James B Breitmeyer, Life Sciences Maste Perceptive, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr.
View institutional ownership trends for Zogenix
.

Which major investors are selling Zogenix stock?

ZGNX stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, WINTON GROUP Ltd, Oak Ridge Investments LLC, Premier Asset Management LLC, GW&K Investment Management LLC, Mutual of America Capital Management LLC, and Arizona State Retirement System. Company insiders that have sold Zogenix company stock in the last year include Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, and Stephen J Farr.
View insider buying and selling activity for Zogenix
.

Which major investors are buying Zogenix stock?

ZGNX stock was acquired by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, SG Americas Securities LLC, Principal Financial Group Inc., Quantitative Systematic Strategies LLC, Swiss National Bank, and Russell Investments Group Ltd.. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, Life Sciences Maste Perceptive, and Mark C Wiggins.
View insider buying and selling activity for Zogenix
.

How do I buy shares of Zogenix?

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zogenix's stock price today?

One share of ZGNX stock can currently be purchased for approximately $23.69.

How big of a company is Zogenix?

Zogenix has a market capitalization of $1.31 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Zogenix employs 90 workers across the globe.

What is Zogenix's official website?

The official website for Zogenix is www.zogenix.com.

How can I contact Zogenix?

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.